Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 5984-5993

  Burvenich, Ingrid J G ^a   Lee, Fook T ^a   Cartwright, Glenn A ^a   O'Keefe, Graeme J ^c   Makris, Dahna ^a   Cao, Diana ^a   Gong, Sylvia ^c   Chueh, Anderly C ^b   Mariadason, John M ^b   Brechbiel, Martin W ^d   Beckman, Robert A ^e   Fujiwara, Kosaku ^f   Von Roemeling, Reinhard ^e   Scott, Andrew M ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c AUSTIN HEALTH   (Australia)

^d Centre for Cancer Research   (United States)

^e DAIICHI SANKYO INC   (United States)

^f DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; INDIUM 111; TIGATUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BALB/C NUDE MOUSE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN COLO 205; CELL STRAIN CT26; CELL STRAIN WIDR; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GAMMA CAMERA; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MAXIMUM PLASMA CONCENTRATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; KINETICS; MICE; MOLECULAR IMAGING; PROTEIN BINDING; RADIONUCLIDE IMAGING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TISSUE DISTRIBUTION;

EID: 84887048123     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3104     Document Type: Article

References (24)

1. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7: 954-60.
2. Yada A, Yazawa M, Ishida S,Yoshida H, Ichikawa K, Kurakata S, et al.A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008;19: 1060-7.
3. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16: 5386-97.
4. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7: 1001-12.
5. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9: 3731-41.
6. DeRosier LC, BuchsbaumDJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, et al. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13: 5535s-43s.
7. Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007;6: 3198-207.
8. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010;25: 13-9.
9. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, et al. Construction, production, and characterization of humanized anti- Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60: 3254-61.
10. Semple TU, Quinn LA, Woods LK, Moore GE. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res 1978;38: 1345-55.
11. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35: 2434-9.
12. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans- CyDTPA. Bioorg Med Chem 1997;5: 1925-34.
13. Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, et al. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res 2001;61: 4474-82.
14. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60: 4804-11.
15. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72: 77-89.
16. Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. Singlephoton emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. Cancer Biol Ther 2007;6: 1396-402.
17. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 1995;72: 1364-72.
18. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolismand retention of iodine-125, yttrium- 90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56: 2123-9.
19. Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. Highresolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 2007;6: 866-75.
20. Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, Rana S, et al. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther 2012;11: 405-15.
21. Rossin R, Kohno T, Hagooly A, Sharp T, Gliniak B, Arroll T, et al. Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. J Nucl Med 2011;52: 942-9.
22. Duiker EW, Dijkers EC, Lambers Heerspink H, de Jong S, van der Zee AG, Jager PL, et al. Development of a radioiodinated apoptosisinducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. Br J Pharmacol 2012;165: 2203-12.
23. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011;19: 101-13.
24. Smith BA, Smith BD. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem 2012;23: 1989-2006.